We think that circulating tumor DNA is good analyte to monitor tumor response to treatment. In NADIM I, the first trial, we already saw that circulating tumor DNA levels correlated well with tumor response. It predicted survival as good as pathological complete response or even better, the capacity to predict survival outcome was even better than imagined techniques. And so here we wanted to do the same with NADIM II...
We think that circulating tumor DNA is good analyte to monitor tumor response to treatment. In NADIM I, the first trial, we already saw that circulating tumor DNA levels correlated well with tumor response. It predicted survival as good as pathological complete response or even better, the capacity to predict survival outcome was even better than imagined techniques. And so here we wanted to do the same with NADIM II. We wanted to validate these results and what I am presenting now is that pretreatment circulating tumor DNA levels correlates well with survival, indicating that this is a good prognostic factor, and it may be used for stratify patients and identify those that are at high risk of progression and death, because they have a high tumor load. And we also have found that circulating tumor DNA correlates well with tumor size in these patients. There is a significant association with circulating tumor DNA levels and tumor size.